A Phase I Study of ZD1839 (Iressa) [gefitinib] in Combination With Irinotecan (Camptosar or CPT-11) and Vincristine in Pediatric Patients With Refractory Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Gefitinib (Primary) ; Irinotecan; Vincristine
- Indications Solid tumours
- Focus Adverse reactions
- 03 Oct 2011 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 03 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.